Originally discovered in bacteria, CRISPR quickly became the workhorse gene-editing system underlying the next generation of programmable medicines. Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases. And it’s a milestone barely......